SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (554)8/5/1999 9:09:00 PM
From: tommysdad  Read Replies (1) of 3158
 
Quoted in BioWorld Today on Tuesday was Gwen Fisher, corporate communications from Merck:

"Basically, the reason we chose Sibia is because they have a high-quality staff doing excellent work in central nervous system [CNS] disorders. It will give us a U.S. presence in CNS research."

and this (WRT BMS and LLY collaborations):

"We intend to honor all of Sibia's contractual obligations. We didn't do this deal in the hopes of getting any products. We see the value in their staff and technology."

So 1508Y and 1553Y stay with Lilly. The Lilly collaboration continues, unless of course LLY wants to back out.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News